BISGIN, A. Et Al. 2009. Increased serum sTRAIL level following BevacizumAb treatment is correlated with patient survival in metastatic colon cancer. 34th Congress of the Federation-of-European-Biochemical-Societies , (Prague, Czech Republic), 301-302.

BISGIN, A., AYDIN, C., Terzioglu, E., YALÇIN, A. N., KARGI, A., SAVAS, B., ... ŞANLIOĞLU, S.(2009). Increased serum sTRAIL level following BevacizumAb treatment is correlated with patient survival in metastatic colon cancer . 34th Congress of the Federation-of-European-Biochemical-Societies (pp.301-302). Prague, Czech Republic

BISGIN, A. Et Al. "Increased serum sTRAIL level following BevacizumAb treatment is correlated with patient survival in metastatic colon cancer," 34th Congress of the Federation-of-European-Biochemical-Societies, Prague, Czech Republic, 2009

BISGIN, A. Et Al. "Increased serum sTRAIL level following BevacizumAb treatment is correlated with patient survival in metastatic colon cancer." 34th Congress of the Federation-of-European-Biochemical-Societies , Prague, Czech Republic, pp.301-302, 2009

BISGIN, A. Et Al. (2009) . "Increased serum sTRAIL level following BevacizumAb treatment is correlated with patient survival in metastatic colon cancer." 34th Congress of the Federation-of-European-Biochemical-Societies , Prague, Czech Republic, pp.301-302.

@conferencepaper{conferencepaper, author={A. BISGIN Et Al. }, title={Increased serum sTRAIL level following BevacizumAb treatment is correlated with patient survival in metastatic colon cancer}, congress name={34th Congress of the Federation-of-European-Biochemical-Societies}, city={Prague}, country={Czech Republic}, year={2009}, pages={301-302} }